Maraviroc: a review of its use in HIV infection and beyond
Shawna M Woollard, Georgette D Kanmogne Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA Abstract: The human immunodeficiency virus-1 (HIV-1) enters target cells by binding its envelope glycoprotein gp120 to the CD4 receptor and/or cor...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-10-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | https://www.dovepress.com/maraviroc-a-review-of-its-use-in-hiv-infection-and-beyond-peer-reviewed-article-DDDT |
| _version_ | 1811310205927948288 |
|---|---|
| author | Woollard SM Kanmogne GD |
| author_facet | Woollard SM Kanmogne GD |
| author_sort | Woollard SM |
| collection | DOAJ |
| description | Shawna M Woollard, Georgette D Kanmogne Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA Abstract: The human immunodeficiency virus-1 (HIV-1) enters target cells by binding its envelope glycoprotein gp120 to the CD4 receptor and/or coreceptors such as C-C chemokine receptor type 5 (CCR5; R5) and C-X-C chemokine receptor type 4 (CXCR4; X4), and R5-tropic viruses predominate during the early stages of infection. CCR5 antagonists bind to CCR5 to prevent viral entry. Maraviroc (MVC) is the only CCR5 antagonist currently approved by the United States Food and Drug Administration, the European Commission, Health Canada, and several other countries for the treatment of patients infected with R5-tropic HIV-1. MVC has been shown to be effective at inhibiting HIV-1 entry into cells and is well tolerated. With expanding MVC use by HIV-1-infected humans, different clinical outcomes post-approval have been observed with MVC monotherapy or combination therapy with other antiretroviral drugs, with MVC use in humans infected with dual-R5- and X4-tropic HIV-1, infected with different HIV-1 genotype or infected with HIV-2. This review discuss the role of CCR5 in HIV-1 infection, the development of the CCR5 antagonist MVC, its pharmacokinetics, pharmacodynamics, drug–drug interactions, and the implications of these interactions on treatment outcomes, including viral mutations and drug resistance, and the mechanisms associated with the development of resistance to MVC. This review also discusses available studies investigating the use of MVC in the treatment of other diseases such as cancer, graft-versus-host disease, and inflammatory diseases. Keywords: chemokine receptors, human immunodeficiency virus, CCR5 antagonists, pharmacokinetics, pharmacodynamics, drug interactions, mutations, resistance, AIDS |
| first_indexed | 2024-04-13T09:55:16Z |
| format | Article |
| id | doaj.art-f32544998dfc487b992387d3c57eebc9 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-13T09:55:16Z |
| publishDate | 2015-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-f32544998dfc487b992387d3c57eebc92022-12-22T02:51:27ZengDove Medical PressDrug Design, Development and Therapy1177-88812015-10-012015default5447546823944Maraviroc: a review of its use in HIV infection and beyondWoollard SMKanmogne GDShawna M Woollard, Georgette D Kanmogne Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA Abstract: The human immunodeficiency virus-1 (HIV-1) enters target cells by binding its envelope glycoprotein gp120 to the CD4 receptor and/or coreceptors such as C-C chemokine receptor type 5 (CCR5; R5) and C-X-C chemokine receptor type 4 (CXCR4; X4), and R5-tropic viruses predominate during the early stages of infection. CCR5 antagonists bind to CCR5 to prevent viral entry. Maraviroc (MVC) is the only CCR5 antagonist currently approved by the United States Food and Drug Administration, the European Commission, Health Canada, and several other countries for the treatment of patients infected with R5-tropic HIV-1. MVC has been shown to be effective at inhibiting HIV-1 entry into cells and is well tolerated. With expanding MVC use by HIV-1-infected humans, different clinical outcomes post-approval have been observed with MVC monotherapy or combination therapy with other antiretroviral drugs, with MVC use in humans infected with dual-R5- and X4-tropic HIV-1, infected with different HIV-1 genotype or infected with HIV-2. This review discuss the role of CCR5 in HIV-1 infection, the development of the CCR5 antagonist MVC, its pharmacokinetics, pharmacodynamics, drug–drug interactions, and the implications of these interactions on treatment outcomes, including viral mutations and drug resistance, and the mechanisms associated with the development of resistance to MVC. This review also discusses available studies investigating the use of MVC in the treatment of other diseases such as cancer, graft-versus-host disease, and inflammatory diseases. Keywords: chemokine receptors, human immunodeficiency virus, CCR5 antagonists, pharmacokinetics, pharmacodynamics, drug interactions, mutations, resistance, AIDShttps://www.dovepress.com/maraviroc-a-review-of-its-use-in-hiv-infection-and-beyond-peer-reviewed-article-DDDT |
| spellingShingle | Woollard SM Kanmogne GD Maraviroc: a review of its use in HIV infection and beyond Drug Design, Development and Therapy |
| title | Maraviroc: a review of its use in HIV infection and beyond |
| title_full | Maraviroc: a review of its use in HIV infection and beyond |
| title_fullStr | Maraviroc: a review of its use in HIV infection and beyond |
| title_full_unstemmed | Maraviroc: a review of its use in HIV infection and beyond |
| title_short | Maraviroc: a review of its use in HIV infection and beyond |
| title_sort | maraviroc a review of its use in hiv infection and beyond |
| url | https://www.dovepress.com/maraviroc-a-review-of-its-use-in-hiv-infection-and-beyond-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT woollardsm maravirocareviewofitsuseinhivinfectionandbeyond AT kanmognegd maravirocareviewofitsuseinhivinfectionandbeyond |